Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-06-02

AUTHORS

Yoshishige Samukawa, Hirohisa Omiya, Hirotaka Watase, Kazunari Nozaki, Soichi Sakai, Rimei Nishimura

ABSTRACT

IntroductionIn our previous study investigating effects of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, on 24-h glycemic variability by continuous glucose monitoring (CGM), luseogliflozin elicited parallel downward shifts in fasting and postprandial glucose levels. However, further review of individual patients’ data revealed that postprandial hyperglycemia was not reduced in some patients, while preprandial glucose was ameliorated in most patients. Therefore, we divided patients into two groups according to their postprandial glucose responses and conducted a post hoc subanalyses to elucidate which factors contributed to the differential effects of luseogliflozin.MethodsThirty-four Japanese type 2 diabetic patients in our previous randomized, double-blind, placebo-controlled, crossover study with 7-day luseogliflozin administration were divided into postprandial glucose responders (PGR, n = 23, ameliorated peak glucose) and postprandial glucose non-responders (PGNR; n = 11, non-ameliorated peak glucose). Baseline characteristics, variations in CGM-measured 24-h glucose levels, and other pharmacodynamic variabilities were compared.ResultsBaseline characteristics did not differ significantly between groups. Placebo-subtracted peak glucose was significantly lowered in PGR and significantly increased in PGNR (−43.8 and 17.9 mg/dL; both p < 0.05). Luseogliflozin significantly lowered “lowest glucose” (defined as the lowest level measured throughout a 24-h period) similarly in PGR and PGNR (−19.2 and −24.0 mg/dL; both p < 0.05), significantly reduced the mean amplitude of glucose excursions in PGR (−15.50 mg/dL; p < 0.05), and increased the area under the curve for plasma glucagon over 24 h in PGNR (median difference vs. placebo: 240 pg/mL h; p < 0.05). Luseogliflozin increased urinary glucose excretion (UGE) and decreased serum insulin by similar magnitudes in both groups.ConclusionsLuseogliflozin diminished glucose fluctuations in most patients by lowering peak glucose to a greater extent than lowest glucose. Luseogliflozin may also lower lowest glucose in patients whose peak glucose was not ameliorated despite increasing UGE. The glucagon increase in PGNR might explain its hypoglycemic effect on postprandial glucose.FundingTaisho Pharmaceutical Co., Ltd, Tokyo, Japan.Trial RegistrationJapicCTI-142548. More... »

PAGES

1215-1230

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5

DOI

http://dx.doi.org/10.1007/s12325-016-0350-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003457836

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27255763


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Over Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hyperglycemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postprandial Period", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sorbitol", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samukawa", 
        "givenName": "Yoshishige", 
        "id": "sg:person.01044115456.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044115456.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Omiya", 
        "givenName": "Hirohisa", 
        "id": "sg:person.01034253641.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034253641.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watase", 
        "givenName": "Hirotaka", 
        "id": "sg:person.01362135451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362135451.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nozaki", 
        "givenName": "Kazunari", 
        "id": "sg:person.01314022251.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314022251.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakai", 
        "givenName": "Soichi", 
        "id": "sg:person.01133661156.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133661156.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Nishi-shimbashi, Minato-ku, 105-0003, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Nishi-shimbashi, Minato-ku, 105-0003, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishimura", 
        "givenName": "Rimei", 
        "id": "sg:person.0745514477.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745514477.90"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrendo.2011.243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038216268", 
          "https://doi.org/10.1038/nrendo.2011.243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-014-0169-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040395366", 
          "https://doi.org/10.1186/s12933-014-0169-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-014-0230-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007759159", 
          "https://doi.org/10.1007/s40265-014-0230-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.3828", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033956920", 
          "https://doi.org/10.1038/nm.3828"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-013-0042-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005579084", 
          "https://doi.org/10.1007/s13300-013-0042-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-015-0200-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027959488", 
          "https://doi.org/10.1007/s12325-015-0200-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12272-014-0419-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048225579", 
          "https://doi.org/10.1007/s12272-014-0419-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-06-02", 
    "datePublishedReg": "2016-06-02", 
    "description": "IntroductionIn our previous study investigating effects of luseogliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, on 24-h glycemic variability by continuous glucose monitoring (CGM), luseogliflozin elicited parallel downward shifts in fasting and postprandial glucose levels. However, further review of individual patients\u2019 data revealed that postprandial hyperglycemia was not reduced in some patients, while preprandial glucose was ameliorated in most patients. Therefore, we divided patients into two groups according to their postprandial glucose responses and conducted a post hoc subanalyses to elucidate which factors contributed to the differential effects of luseogliflozin.MethodsThirty-four Japanese type 2 diabetic patients in our previous randomized, double-blind, placebo-controlled, crossover study with 7-day luseogliflozin administration were divided into postprandial glucose responders (PGR, n\u00a0=\u00a023, ameliorated peak glucose) and postprandial glucose non-responders (PGNR; n\u00a0=\u00a011, non-ameliorated peak glucose). Baseline characteristics, variations in CGM-measured 24-h glucose levels, and other pharmacodynamic variabilities were compared.ResultsBaseline characteristics did not differ significantly between groups. Placebo-subtracted peak glucose was significantly lowered in PGR and significantly increased in PGNR (\u221243.8 and 17.9\u00a0mg/dL; both p\u00a0<\u00a00.05). Luseogliflozin significantly lowered \u201clowest glucose\u201d (defined as the lowest level measured throughout a 24-h period) similarly in PGR and PGNR (\u221219.2 and \u221224.0\u00a0mg/dL; both p\u00a0<\u00a00.05), significantly reduced the mean amplitude of glucose excursions in PGR (\u221215.50\u00a0mg/dL; p\u00a0<\u00a00.05), and increased the area under the curve for plasma glucagon over 24\u00a0h in PGNR (median difference vs. placebo: 240\u00a0pg/mL\u00a0h; p\u00a0<\u00a00.05). Luseogliflozin increased urinary glucose excretion (UGE) and decreased serum insulin by similar magnitudes in both groups.ConclusionsLuseogliflozin diminished glucose fluctuations in most patients by lowering peak glucose to a greater extent than lowest glucose. Luseogliflozin may also lower lowest glucose in patients whose peak glucose was not ameliorated despite increasing UGE. The glucagon increase in PGNR might explain its hypoglycemic effect on postprandial glucose.FundingTaisho Pharmaceutical Co., Ltd, Tokyo, Japan.Trial RegistrationJapicCTI-142548.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12325-016-0350-5", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096634", 
        "issn": [
          "0741-238X", 
          "1865-8652"
        ], 
        "name": "Advances in Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "33"
      }
    ], 
    "keywords": [
      "urinary glucose excretion", 
      "continuous glucose monitoring", 
      "peak glucose", 
      "most patients", 
      "postprandial glucose", 
      "postprandial hyperglycemia", 
      "low glucose", 
      "glucose levels", 
      "Japanese type 2 diabetic patients", 
      "sodium-glucose cotransporter 2 inhibitors", 
      "type 2 diabetic patients", 
      "effect of luseogliflozin", 
      "cotransporter 2 inhibitors", 
      "postprandial glucose levels", 
      "postprandial glucose response", 
      "parallel downward shift", 
      "luseogliflozin administration", 
      "ResultsBaseline characteristics", 
      "baseline characteristics", 
      "glucose excretion", 
      "diabetic patients", 
      "serum insulin", 
      "crossover study", 
      "plasma glucagon", 
      "glucagon increase", 
      "preprandial glucose", 
      "pharmacodynamic variability", 
      "glycemic variability", 
      "glucose excursions", 
      "Controlled Study", 
      "individual patients", 
      "luseogliflozin", 
      "glucose fluctuations", 
      "hypoglycemic effect", 
      "patients", 
      "glucose response", 
      "glucose monitoring", 
      "further review", 
      "hyperglycemia", 
      "mean amplitude", 
      "subanalyses", 
      "Analyzing Responses", 
      "differential effects", 
      "PgR", 
      "glucose", 
      "group", 
      "previous studies", 
      "similar magnitude", 
      "glucagon", 
      "responders", 
      "excretion", 
      "insulin", 
      "administration", 
      "response", 
      "study", 
      "greater extent", 
      "levels", 
      "effect", 
      "inhibitors", 
      "review", 
      "substantial effect", 
      "factors", 
      "downward shift", 
      "increase", 
      "variability", 
      "excursion", 
      "monitoring", 
      "characteristics", 
      "extent", 
      "data", 
      "curves", 
      "Japan", 
      "area", 
      "amplitude", 
      "Ltd", 
      "Tokyo", 
      "magnitude", 
      "variation", 
      "shift", 
      "fluctuations", 
      "Co."
    ], 
    "name": "Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study", 
    "pagination": "1215-1230", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003457836"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12325-016-0350-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27255763"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12325-016-0350-5", 
      "https://app.dimensions.ai/details/publication/pub.1003457836"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_720.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12325-016-0350-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      21 PREDICATES      127 URIs      112 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12325-016-0350-5 schema:about N2bcd85e24e014547b9413c5ffe14f0a3
2 N46fa478a6bab420f99fbed9d1a472114
3 N55e444a4ad154ff1a4e25a4d9c94447c
4 N5f111a21ff0840fe8c9196eab5523ae6
5 N649cac938af04c47b9e653094e2a5e66
6 N80c38acaa9bf4e09a8fda4f5e8b69c04
7 N8adeeb916e424eef88e21625ff416ab8
8 N8e8a18a001564b05b34c0281cf45e38a
9 Nb87fa557713b4ff3996c12264cd07417
10 Nba1cbce13ecd4237b387c1b31638944a
11 Nc43fd0d4e3fa480e8d40c4eec260cee8
12 Nd47ccf29280440ccb2e1027f8c72190e
13 Nf1baac74a4734f3da90bc8e713e16f26
14 Nf6c683b72a2f475c99db0a23c80499ea
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nbcc53be9ac03470ab38419165e0e891f
18 schema:citation sg:pub.10.1007/s12272-014-0419-0
19 sg:pub.10.1007/s12325-015-0200-x
20 sg:pub.10.1007/s13300-013-0042-y
21 sg:pub.10.1007/s40265-014-0230-8
22 sg:pub.10.1038/nm.3828
23 sg:pub.10.1038/nrendo.2011.243
24 sg:pub.10.1186/s12933-014-0169-9
25 schema:datePublished 2016-06-02
26 schema:datePublishedReg 2016-06-02
27 schema:description IntroductionIn our previous study investigating effects of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, on 24-h glycemic variability by continuous glucose monitoring (CGM), luseogliflozin elicited parallel downward shifts in fasting and postprandial glucose levels. However, further review of individual patients’ data revealed that postprandial hyperglycemia was not reduced in some patients, while preprandial glucose was ameliorated in most patients. Therefore, we divided patients into two groups according to their postprandial glucose responses and conducted a post hoc subanalyses to elucidate which factors contributed to the differential effects of luseogliflozin.MethodsThirty-four Japanese type 2 diabetic patients in our previous randomized, double-blind, placebo-controlled, crossover study with 7-day luseogliflozin administration were divided into postprandial glucose responders (PGR, n = 23, ameliorated peak glucose) and postprandial glucose non-responders (PGNR; n = 11, non-ameliorated peak glucose). Baseline characteristics, variations in CGM-measured 24-h glucose levels, and other pharmacodynamic variabilities were compared.ResultsBaseline characteristics did not differ significantly between groups. Placebo-subtracted peak glucose was significantly lowered in PGR and significantly increased in PGNR (−43.8 and 17.9 mg/dL; both p < 0.05). Luseogliflozin significantly lowered “lowest glucose” (defined as the lowest level measured throughout a 24-h period) similarly in PGR and PGNR (−19.2 and −24.0 mg/dL; both p < 0.05), significantly reduced the mean amplitude of glucose excursions in PGR (−15.50 mg/dL; p < 0.05), and increased the area under the curve for plasma glucagon over 24 h in PGNR (median difference vs. placebo: 240 pg/mL h; p < 0.05). Luseogliflozin increased urinary glucose excretion (UGE) and decreased serum insulin by similar magnitudes in both groups.ConclusionsLuseogliflozin diminished glucose fluctuations in most patients by lowering peak glucose to a greater extent than lowest glucose. Luseogliflozin may also lower lowest glucose in patients whose peak glucose was not ameliorated despite increasing UGE. The glucagon increase in PGNR might explain its hypoglycemic effect on postprandial glucose.FundingTaisho Pharmaceutical Co., Ltd, Tokyo, Japan.Trial RegistrationJapicCTI-142548.
28 schema:genre article
29 schema:isAccessibleForFree true
30 schema:isPartOf N3ec3da3e0cd24ad6a8fa07940c18e9b2
31 Ne54f96ffdd9247de974652d10dcb94fc
32 sg:journal.1096634
33 schema:keywords Analyzing Responses
34 Co.
35 Controlled Study
36 Japan
37 Japanese type 2 diabetic patients
38 Ltd
39 PgR
40 ResultsBaseline characteristics
41 Tokyo
42 administration
43 amplitude
44 area
45 baseline characteristics
46 characteristics
47 continuous glucose monitoring
48 cotransporter 2 inhibitors
49 crossover study
50 curves
51 data
52 diabetic patients
53 differential effects
54 downward shift
55 effect
56 effect of luseogliflozin
57 excretion
58 excursion
59 extent
60 factors
61 fluctuations
62 further review
63 glucagon
64 glucagon increase
65 glucose
66 glucose excretion
67 glucose excursions
68 glucose fluctuations
69 glucose levels
70 glucose monitoring
71 glucose response
72 glycemic variability
73 greater extent
74 group
75 hyperglycemia
76 hypoglycemic effect
77 increase
78 individual patients
79 inhibitors
80 insulin
81 levels
82 low glucose
83 luseogliflozin
84 luseogliflozin administration
85 magnitude
86 mean amplitude
87 monitoring
88 most patients
89 parallel downward shift
90 patients
91 peak glucose
92 pharmacodynamic variability
93 plasma glucagon
94 postprandial glucose
95 postprandial glucose levels
96 postprandial glucose response
97 postprandial hyperglycemia
98 preprandial glucose
99 previous studies
100 responders
101 response
102 review
103 serum insulin
104 shift
105 similar magnitude
106 sodium-glucose cotransporter 2 inhibitors
107 study
108 subanalyses
109 substantial effect
110 type 2 diabetic patients
111 urinary glucose excretion
112 variability
113 variation
114 schema:name Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
115 schema:pagination 1215-1230
116 schema:productId N89b745a0f42544648b81e874cee48fa6
117 Nd6b5b81c009841238f9eb7d6d1150d20
118 Ned0664153b334c3caa02a8898ce73e8e
119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003457836
120 https://doi.org/10.1007/s12325-016-0350-5
121 schema:sdDatePublished 2022-09-02T16:01
122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
123 schema:sdPublisher N16060e552b7b483fb810fcb07d409206
124 schema:url https://doi.org/10.1007/s12325-016-0350-5
125 sgo:license sg:explorer/license/
126 sgo:sdDataset articles
127 rdf:type schema:ScholarlyArticle
128 N16060e552b7b483fb810fcb07d409206 schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 N2493a0fcd09248a9a4ac79152a878562 rdf:first sg:person.01034253641.66
131 rdf:rest Nda4da477dd814cc9a3f861d7895f3e37
132 N2bcd85e24e014547b9413c5ffe14f0a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Female
134 rdf:type schema:DefinedTerm
135 N3ec3da3e0cd24ad6a8fa07940c18e9b2 schema:issueNumber 7
136 rdf:type schema:PublicationIssue
137 N46fa478a6bab420f99fbed9d1a472114 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Male
139 rdf:type schema:DefinedTerm
140 N55e444a4ad154ff1a4e25a4d9c94447c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Postprandial Period
142 rdf:type schema:DefinedTerm
143 N5f111a21ff0840fe8c9196eab5523ae6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Aged
145 rdf:type schema:DefinedTerm
146 N649cac938af04c47b9e653094e2a5e66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Japan
148 rdf:type schema:DefinedTerm
149 N780702ce8504490db15438711403a31d rdf:first sg:person.01133661156.29
150 rdf:rest Nbb80eac8c681434b835cc2722a95ff1d
151 N80c38acaa9bf4e09a8fda4f5e8b69c04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Middle Aged
153 rdf:type schema:DefinedTerm
154 N89b745a0f42544648b81e874cee48fa6 schema:name pubmed_id
155 schema:value 27255763
156 rdf:type schema:PropertyValue
157 N8adeeb916e424eef88e21625ff416ab8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Hypoglycemic Agents
159 rdf:type schema:DefinedTerm
160 N8e8a18a001564b05b34c0281cf45e38a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Cross-Over Studies
162 rdf:type schema:DefinedTerm
163 Nb87fa557713b4ff3996c12264cd07417 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Diabetes Mellitus, Type 2
165 rdf:type schema:DefinedTerm
166 Nba1cbce13ecd4237b387c1b31638944a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Double-Blind Method
168 rdf:type schema:DefinedTerm
169 Nbb80eac8c681434b835cc2722a95ff1d rdf:first sg:person.0745514477.90
170 rdf:rest rdf:nil
171 Nbcc53be9ac03470ab38419165e0e891f rdf:first sg:person.01044115456.01
172 rdf:rest N2493a0fcd09248a9a4ac79152a878562
173 Nc43fd0d4e3fa480e8d40c4eec260cee8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Blood Glucose
175 rdf:type schema:DefinedTerm
176 Nd47ccf29280440ccb2e1027f8c72190e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Hyperglycemia
178 rdf:type schema:DefinedTerm
179 Nd52835137bff402d9d39caaee6e65e1a rdf:first sg:person.01314022251.64
180 rdf:rest N780702ce8504490db15438711403a31d
181 Nd6b5b81c009841238f9eb7d6d1150d20 schema:name dimensions_id
182 schema:value pub.1003457836
183 rdf:type schema:PropertyValue
184 Nda4da477dd814cc9a3f861d7895f3e37 rdf:first sg:person.01362135451.72
185 rdf:rest Nd52835137bff402d9d39caaee6e65e1a
186 Ne54f96ffdd9247de974652d10dcb94fc schema:volumeNumber 33
187 rdf:type schema:PublicationVolume
188 Ned0664153b334c3caa02a8898ce73e8e schema:name doi
189 schema:value 10.1007/s12325-016-0350-5
190 rdf:type schema:PropertyValue
191 Nf1baac74a4734f3da90bc8e713e16f26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Humans
193 rdf:type schema:DefinedTerm
194 Nf6c683b72a2f475c99db0a23c80499ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Sorbitol
196 rdf:type schema:DefinedTerm
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
201 schema:name Clinical Sciences
202 rdf:type schema:DefinedTerm
203 sg:journal.1096634 schema:issn 0741-238X
204 1865-8652
205 schema:name Advances in Therapy
206 schema:publisher Springer Nature
207 rdf:type schema:Periodical
208 sg:person.01034253641.66 schema:affiliation grid-institutes:grid.419836.1
209 schema:familyName Omiya
210 schema:givenName Hirohisa
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034253641.66
212 rdf:type schema:Person
213 sg:person.01044115456.01 schema:affiliation grid-institutes:grid.419836.1
214 schema:familyName Samukawa
215 schema:givenName Yoshishige
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044115456.01
217 rdf:type schema:Person
218 sg:person.01133661156.29 schema:affiliation grid-institutes:grid.419836.1
219 schema:familyName Sakai
220 schema:givenName Soichi
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133661156.29
222 rdf:type schema:Person
223 sg:person.01314022251.64 schema:affiliation grid-institutes:grid.419836.1
224 schema:familyName Nozaki
225 schema:givenName Kazunari
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314022251.64
227 rdf:type schema:Person
228 sg:person.01362135451.72 schema:affiliation grid-institutes:grid.419836.1
229 schema:familyName Watase
230 schema:givenName Hirotaka
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362135451.72
232 rdf:type schema:Person
233 sg:person.0745514477.90 schema:affiliation grid-institutes:grid.411898.d
234 schema:familyName Nishimura
235 schema:givenName Rimei
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745514477.90
237 rdf:type schema:Person
238 sg:pub.10.1007/s12272-014-0419-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048225579
239 https://doi.org/10.1007/s12272-014-0419-0
240 rdf:type schema:CreativeWork
241 sg:pub.10.1007/s12325-015-0200-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027959488
242 https://doi.org/10.1007/s12325-015-0200-x
243 rdf:type schema:CreativeWork
244 sg:pub.10.1007/s13300-013-0042-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1005579084
245 https://doi.org/10.1007/s13300-013-0042-y
246 rdf:type schema:CreativeWork
247 sg:pub.10.1007/s40265-014-0230-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007759159
248 https://doi.org/10.1007/s40265-014-0230-8
249 rdf:type schema:CreativeWork
250 sg:pub.10.1038/nm.3828 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033956920
251 https://doi.org/10.1038/nm.3828
252 rdf:type schema:CreativeWork
253 sg:pub.10.1038/nrendo.2011.243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038216268
254 https://doi.org/10.1038/nrendo.2011.243
255 rdf:type schema:CreativeWork
256 sg:pub.10.1186/s12933-014-0169-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040395366
257 https://doi.org/10.1186/s12933-014-0169-9
258 rdf:type schema:CreativeWork
259 grid-institutes:grid.411898.d schema:alternateName Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Nishi-shimbashi, Minato-ku, 105-0003, Tokyo, Japan
260 schema:name Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Nishi-shimbashi, Minato-ku, 105-0003, Tokyo, Japan
261 rdf:type schema:Organization
262 grid-institutes:grid.419836.1 schema:alternateName Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan
263 schema:name Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...